Considering that high levels of RIPK3 expression and low level of TRIM28 expression in human gastric cancer tumors correlate with improved gastric cancer patient survival, we propose that patients who have a high level of TRIM28 expression in tumor tissue will get a beneficial effect with an improved level of RIPK3 activation using intra-tumoral treatment of RIPK3 agonist in the case of high expression of RIPK3 and adeno-associated viruses (AAVs)-mediated delivery of constitutively-active RIPK3 in case of little or no expression of RIPK3. The gene discussed is RIPK3; the disease is gastric cancer.